Executive committee

Fabrizio Greco - AbbVie
President

President of Assobiotec for 2022-2025. General Manager of Abbvie Italy since 2013 and of Abbott PPD since 2011. Past president of the IAPG (American Pharmaceutical group industry Association).
He began his career in 1991 as Financial Analyst at Ely Lilly and in 1994, after the split of the Medical Devices and Diagnostic division of Eli Lilly (that created Guidant), he was appointed Finance and  HR manager of Guidant Italy. During the years he covered commercial roles of increasing responsibilities including General Manager Guidant Portugal in 2002 and General Manager Abbott Vascular Italy in 2006. Education: Degree in Electronic Engineering from the University of Genova and Master’s degree in Business Administration from the Bocconi University of Milan.  

Riccardo Palmisano - DiaSorin
Past President

Riccardo Palmisano currently holds the following positions: CEO InnovaVector, Consultant DiaSorin SpA, Senior Advisor for Triton, Quadrivio, EIM.
A graduate in Medicine and Surgery, he began his career at Farmitalia Carlo Erba (1986), then moved to the Menarini Group (1988), where he became Director of the Pharmaceutical Division Italy in 1993 and General Manager of Lusofarmaco in 1995. In 2000 he founded as CEO the Italian subsidiary of Shire Pharmaceutical, in 2003 he was Vice President Commercial Retail Market in GlaxoSmithKline and in 2005 Managing Director in Genzyme. Following the acquisition by Sanofi, from 2012 he added the role of Head of Business Development of Sanofi Italia. From 2015 to 2020 he was CEO of MolMed SpA, a company listed on the Milan Stock Exchange, leading its transformation from an R&D company to a CDMO in the Advanced Therapies area, guiding it to break-even and its acquisition by the AGC Biologics Group for € 240 million. In Assobiotec since 2008, he became Vice President in 2010 and was elected President in 2016, then confirmed for the three-year period 2019-22. He was also Vice President of the Cluster Lombardo Scienze della Vita of Assolombarda.

Elena Sgaravatti - PlantaRei Biotech
Vice President

Elena Sgaravatti is PlantaRei President, Co-founder and shareholder of Demethra Biotech Srl. After graduating with a Pharm. D. degree from Padova University, she developed more than twenty years of experience in the pharmaceutical sector, from business development to strategic marketing in multinational companies such as GSK. She was CEO at IRB Spa (Biotechnological Research Institute) until June 2016, a company she launched in 2009, when she joined as General Director, which was acquired by Croda Int. Plc, in 2012. In 2016 she founded, together with Cereal Docks Group, Demethra Biotech S.r.l., an innovative start-up of green biotech. She is the inventor of eleven patents, she is member  of the Academic Commission of the University of Medical Biotechnology of Modena and as well as of the Scientific Committee of the Cluster Bioinnova (Biological Cluster Veneto). She has been a member of the working group for the accreditation and evaluation of the Master’s Degree Program in Biotechnology for Food at the Agripolis University of Padua since 2019. Winner of  #GreenBiotech Award Tecnovisionarie 2020.

Carlo Rosa - DiaSorin Italia
Vice President

Carlo Rosa is Chief Executive Officer of the Diasorin Group. Born in 1966, he graduated in 1990 in Chemistry cum laude from the University of Turin. In 1990, he moved to New York to work at the Health Research Institute on a project to develop a new innovative product for the diagnosis of hepatitis C infections. In 1992, he joined the listed American Incstar Corporation (Minnesota), where he worked in the Research and Development department and led a joint venture project with Akzo Nobel. Subsequently, he held other positions, both in the Research sector and in Strategic Marketing, until assuming the role of Director of the Infectious Diseases Business Unit. In 1998, he returned to Italy to take on the role of Director of Strategy and Marketing Europe for DiaSorin S.p.A. In 2000 he led a management buyout with other executives and a group of financial investors to buy Diasorin from the previous owner, American Standard Inc. Following the transaction, he served as Chief Operating Officer until 2006, when he became CEO of the Group, a position he still holds.

Federico Viganò - Vertex Pharmaceutical
Member

Federico Viganò is Country Manager for Italy and Greece of Vertex Pharmaceuticals. He has a CTF degree from the University of Milan, an Executive MBA from Imperial College London and a master's degree in Chinese history from Trinity College Dublin. After ten years experience, in Italy and abroad, in the GSK vaccine area, he worked in Astrazeneca as Vice President in the cardiovascular and respiratory areas and then as Country President for Ireland.

Pierluigi Paracchi - Genenta Science
Member

Pierluigi Paracchi is an experienced venture capital investor, Founder and CEO of Quantica SGR, co-founder of Axòn Capital and AurorA Science and previously Venture Consultant at Sofinnova Partners. He was also an investor in and Board Member of Ethical Oncology Science, which was acquired in 2013 in a total deal of $400+ million. He also serves as non-executive Director of the autoimmune disease company Altheia Science, non-executive Chairman at Lipogems International (Medical Device for Processing Adipose Tissue).